57. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K
mutation among melanoma patients with BRAF mutations, and
potential therapeutic response to the specific BRAF inhibitor
PLX4032. J Transl Med 2010;8:67.
58. Lovly CM, Dahlman KB, Fohn LE, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE 2012;7:e35309.
59. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
60. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF
inhibitors transactivate RAF dimers and ERK signalling in cells
with wild-type BRAF. Nature 2010;464:427–30.
61. Thomas NE, Edmiston SN, Alexander A, et al. Association
between NRAS and BRAF mutational status and melanoma-spe-cific survival among patients with higher-risk primary melanoma.
JAMA Oncology 2015;1:359–68.
62. Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS
mutations with clinical response to high-dose IL- 2 in patients with
advanced melanoma. J Immunother 2012;35:66–72.
63. Johnson DB, Lovly CM, Flavin M, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune
therapies. Cancer Immunol Res 2015;3:288–95.
64. Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next
generation sequencing identifies markers of response to PD- 1
blockade. Cancer Immunol Res 2016;4:959–67.
65. Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and
melanoma. Lab Invest 2017;97:146–57.
66. Nissan MH, Pratilas CA, Jones AM, et al. Loss of NF1 in cutaneous
melanoma is associated with RAS activation and MEK dependence. Cancer Res 2014;74:2340–50.
67. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients
with advanced malignancies. J Clin Oncol 2005;23:5281–93.
68. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II
study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
J Clin Oncol 2004;22:4456–62.
69. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label,
randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555–67.
70. Davar D, Kirkwood JM. CCR 20th anniversary commentary:
MAPK/ERK pathway inhibition in melanoma-kinase inhibition
redux. Clin Cancer Res 2015;21:5412–4.
71. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous
squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207–15.
72. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance
to RAF inhibition through MAP kinase pathway reactivation.
73. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance
to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
74. Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifies an
adaptive melanoma response to BRAF inhibition. Cancer Discov
75. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal
evolution in melanoma during BRAF inhibitor therapy. Cancer
76. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape
of clinical resistance to RAF inhibition in metastatic melanoma.
Cancer Discov 2014;4:94–109.
77. Flaherty KT, Robert C, Hersey P, et al. Improved survival with
MEK inhibition in BRAF-mutated melanoma. N Engl J Med
78. Dummer R, Ascierto PA, Gogas HJ, et al. Results of COLUMBUS
Part 1: a phase 3 trial of encorafenib (ENCO) plus binimetinib
(BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant
melanoma. Presented at Society for Melanoma Research 2016
Congress. November 6-9, 2016. Boston (MA).
79. Adelmann CH, Ching G, Du L, et al. Comparative profiles of
BRAF inhibitors: the paradox index as a predictor of clinical
toxicity. Oncotarget 2016;7:30453–60.
80. Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3
trial. Lancet Oncol 2017;18:435–45.
81. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human
malignant melanoma: detection of BRAF- and c-kit-activating
mutations by high-resolution amplicon melting analysis. Hum
82. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res
83. Handolias D, Salemi R, Murray W, et al. Mutations in KIT occur
at low frequency in melanomas arising from anatomical sites
associated with chronic and intermittent sun exposure. Pigment
Cell Melanoma Res 2010;23:210– 5.
84. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of
imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904–9.
85. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for
melanomas harboring mutationally activated or amplified KIT
arising on mucosal, acral, and chronically sun-damaged skin. J
Clin Oncol 2013;31:3182–90.
86. Flaherty KT, Hamilton BK, Rosen MA, et al. Phase I/II trial of
imatinib and bevacizumab in patients with advanced melanoma
and other advanced cancers. Oncologist 2015;20:952–9.
87. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid
leukemia in chronic phase: 48-month follow-up results of a phase
II study. Leukemia 2013;27:107–12.
88. Reinwald M, Schleyer E, Kiewe P, et al. Efficacy and pharmaco-logic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous
system relapse after allogeneic stem cell transplantation. Biomed
Res Int 2014;2014:637059.
89. Carvajal RD, Lawrence DP, Weber JS, et al. Phase II study of
nilotinib in melanoma harboring KIT alterations following
progression to prior KIT inhibition. Clin Cancer Res 2015;21:
90. Carlino MS, Todd JR, Gowrishankar K, et al. Differential activity
of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014;8:544–54.
91. Carlino MS, Gowrishankar K, Saunders CAB, et al. Antiprolifera-tive effects of continued mitogen-activated protein kinase pathway
inhibition following acquired resistance to BRAF and/or MEK
inhibition in melanoma. Mol Cancer Ther 2013;12:1332–42.
92. Chan MMK, Haydu LE, Menzies AM, et al. The nature and
management of metastatic melanoma after progression on
BRAF inhibitors: effects of extended BRAF inhibition. Cancer
93. Thakur M Das, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall
drug resistance. Nature 2013;494:251–5.